(1 - 15 von 26
)
Neurocrine's neurological disorder drug effective in late: stage studywww.reuters.com › article
www.reuters.com
— The drug, Xenazine, costs about $90,000 per year, said Zacks Investment Research Inc's analyst David Bautz, adding that he expects NBI
Global Distribution Deal for Antibiotic Alternative for Livestock ...
www.investorideas.com
October 26, (Investorideas.com Newswire) Analyst David Bautz at Zacks Small-Cap Research wrote bullishly on Avivagen's eight-year distribution deal ... › bi...
Market Analysts see ContraFect Corporation [CFRX] gaining to $1 ...dbtnews.com › › market-analysts-see-co...
dbtnews.com
vor 4 Tagen — By David Bautz, PhD. A sum of shares traded at recent session while its average daily volume was at 1.97M shares.
Stock of ContraFect Corporation (CFRX) performance MZP Newsmzpnews.com › › September › 6
mzpnews.com
vor 17 Stunden — In a post published today on Yahoo Finance, By David Bautz, PhD. From an analyst's perspective: ContraFect Corporation [NASDAQ: CFRX] stock has ...
sortiert nach Relevanz / Datum